AI still cannot develop effective vaccines or drugs on its own
Artificial intelligence has made progress in protein analysis and molecule design, but it has not yet shown it can develop effective drugs autonomously. Vertex Pharmaceuticals tested about 50 AI-specialized companies to analyze some 10,000 compounds and none of the proposals became a viable drug. Tools such as Google DeepMind's AlphaFold and companies like Insilico Medicine, Recursion Pharmaceuticals and Isomorphic Labs aim to cut timelines and costs, while scientists argue AI should complement, not replace, clinical experimentation.
In 40 seconds
- Vertex Pharmaceuticals tested about 50 AI companies with some 10,000 compounds and none became a viable drug.
- Google DeepMind's AlphaFold improved protein structure prediction and paved the way for molecule design with generative AI.
- Insilico Medicine, Recursion Pharmaceuticals and Isomorphic Labs aim to cut drug discovery timelines and costs.
Read the full story at La FM
IASummary generated by artificial intelligence from a story by La FM. It may contain errors: the original source prevails.
Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.